Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

- CTx-PDE6b demonstrated clinically meaningful…

Coave Therapeutics Strengthens Board of Directors

Paris, France, October 20th, 2022…

Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

Coave Therapeutics to Collaborate with…

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Coave Therapeutics appoints Olivier Danos…